HEADER SIGNALING PROTEIN/ANTAGONIST 20-SEP-17 6B33 TITLE STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 3 COMPND MOL_ID: 1; COMPND 2 MOLECULE: NUCLEAR RECEPTOR ROR-GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: NUCLEAR RECEPTOR RZR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 COMPND 5 GROUP F MEMBER 3,RAR-RELATED ORPHAN RECEPTOR C,RETINOID-RELATED COMPND 6 ORPHAN RECEPTOR-GAMMA; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: RORC, NR1F3, RORG, RZRG; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS COMPLEX, INVERSE AGONIST, NUCLEAR HORMONE RECEPTOR, SIGNALING KEYWDS 2 PROTEIN-ANTAGONIST COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR R.J.SKENE,I.HOFFMAN,G.SNELL REVDAT 3 13-MAR-24 6B33 1 REMARK REVDAT 2 06-NOV-19 6B33 1 JRNL REVDAT 1 21-NOV-18 6B33 0 JRNL AUTH A.SATO,Y.FUKASE,M.KONO,A.OCHIDA,T.ODA,Y.SASAKI,N.ISHII, JRNL AUTH 2 Y.TOMATA,S.FUKUMOTO,Y.N.IMAI,K.UGA,A.SHIBATA,M.YAMASAKI, JRNL AUTH 3 H.NAKAGAWA,M.SHIRASAKI,R.SKENE,I.HOFFMAN,B.C.SANG,G.SNELL, JRNL AUTH 4 J.SHIRAI,S.YAMAMOTO JRNL TITL DESIGN AND SYNTHESIS OF CONFORMATIONALLY CONSTRAINED ROR JRNL TITL 2 GAMMA T INVERSE AGONISTS. JRNL REF CHEMMEDCHEM 2019 JRNL REFN ESSN 1860-7187 JRNL PMID 31659845 JRNL DOI 10.1002/CMDC.201900416 REMARK 2 REMARK 2 RESOLUTION. 2.48 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.48 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 39.01 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 23651 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.239 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1268 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3524 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 80 REMARK 3 SOLVENT ATOMS : 125 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 66.52 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.08000 REMARK 3 B22 (A**2) : 0.08000 REMARK 3 B33 (A**2) : -0.27000 REMARK 3 B12 (A**2) : 0.04000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.322 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.241 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.207 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 19.779 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS U VALUES : WITH TLS ADDED REMARK 4 REMARK 4 6B33 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 21-SEP-17. REMARK 100 THE DEPOSITION ID IS D_1000230191. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 19-DEC-13 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.98 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315R REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24960 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.480 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 8.100 REMARK 200 R MERGE (I) : 0.07500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.48 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.52 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 7.90 REMARK 200 R MERGE FOR SHELL (I) : 0.87700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 65.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.53 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.6M SODIUM FORMATE, 3% MPD, AND 100 REMARK 280 MM HEPES (PH 7.5), VAPOR DIFFUSION, SITTING DROP, TEMPERATURE REMARK 280 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 61 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+5/6 REMARK 290 6555 X-Y,X,Z+1/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 42.11067 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 84.22133 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 63.16600 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 105.27667 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 21.05533 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 437 CG CD NE CZ NH1 NH2 REMARK 470 ARG B 288 CG CD NE CZ NH1 NH2 REMARK 470 GLU B 303 CG CD OE1 OE2 REMARK 470 LYS B 354 CG CD CE NZ REMARK 470 GLU B 395 CG CD OE1 OE2 REMARK 470 ARG B 437 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 286 -62.17 86.68 REMARK 500 GLN B 286 -55.96 82.80 REMARK 500 CYS B 393 68.41 -151.83 REMARK 500 GLU B 435 67.47 -119.03 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A1162 DISTANCE = 6.13 ANGSTROMS REMARK 525 HOH A1163 DISTANCE = 6.31 ANGSTROMS REMARK 525 HOH A1164 DISTANCE = 6.32 ANGSTROMS REMARK 525 HOH A1165 DISTANCE = 6.53 ANGSTROMS REMARK 525 HOH A1166 DISTANCE = 6.98 ANGSTROMS REMARK 525 HOH B1156 DISTANCE = 5.82 ANGSTROMS REMARK 525 HOH B1157 DISTANCE = 5.83 ANGSTROMS REMARK 525 HOH B1158 DISTANCE = 6.50 ANGSTROMS REMARK 525 HOH B1159 DISTANCE = 7.59 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CF7 A 1000 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CF7 B 1000 DBREF 6B33 A 265 482 UNP P51449 RORG_HUMAN 265 482 DBREF 6B33 B 265 482 UNP P51449 RORG_HUMAN 265 482 SEQRES 1 A 218 ALA SER LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL SEQRES 2 A 218 CYS LYS SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU SEQRES 3 A 218 ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU SEQRES 4 A 218 GLU VAL THR GLY TYR GLN ARG LYS SER MET TRP GLU MET SEQRES 5 A 218 TRP GLU ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN SEQRES 6 A 218 TYR VAL VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET SEQRES 7 A 218 GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA SEQRES 8 A 218 GLY ALA MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA SEQRES 9 A 218 TYR ASN ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS SEQRES 10 A 218 TYR GLY GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER SEQRES 11 A 218 GLU LEU ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SEQRES 12 A 218 SER ALA LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR SEQRES 13 A 218 THR ALA LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU SEQRES 14 A 218 GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU SEQRES 15 A 218 GLU LEU ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG SEQRES 16 A 218 GLN SER ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU SEQRES 17 A 218 ARG SER LEU CYS SER GLN HIS VAL GLU ARG SEQRES 1 B 218 ALA SER LEU THR GLU ILE GLU HIS LEU VAL GLN SER VAL SEQRES 2 B 218 CYS LYS SER TYR ARG GLU THR CYS GLN LEU ARG LEU GLU SEQRES 3 B 218 ASP LEU LEU ARG GLN ARG SER ASN ILE PHE SER ARG GLU SEQRES 4 B 218 GLU VAL THR GLY TYR GLN ARG LYS SER MET TRP GLU MET SEQRES 5 B 218 TRP GLU ARG CYS ALA HIS HIS LEU THR GLU ALA ILE GLN SEQRES 6 B 218 TYR VAL VAL GLU PHE ALA LYS ARG LEU SER GLY PHE MET SEQRES 7 B 218 GLU LEU CYS GLN ASN ASP GLN ILE VAL LEU LEU LYS ALA SEQRES 8 B 218 GLY ALA MET GLU VAL VAL LEU VAL ARG MET CYS ARG ALA SEQRES 9 B 218 TYR ASN ALA ASP ASN ARG THR VAL PHE PHE GLU GLY LYS SEQRES 10 B 218 TYR GLY GLY MET GLU LEU PHE ARG ALA LEU GLY CYS SER SEQRES 11 B 218 GLU LEU ILE SER SER ILE PHE ASP PHE SER HIS SER LEU SEQRES 12 B 218 SER ALA LEU HIS PHE SER GLU ASP GLU ILE ALA LEU TYR SEQRES 13 B 218 THR ALA LEU VAL LEU ILE ASN ALA HIS ARG PRO GLY LEU SEQRES 14 B 218 GLN GLU LYS ARG LYS VAL GLU GLN LEU GLN TYR ASN LEU SEQRES 15 B 218 GLU LEU ALA PHE HIS HIS HIS LEU CYS LYS THR HIS ARG SEQRES 16 B 218 GLN SER ILE LEU ALA LYS LEU PRO PRO LYS GLY LYS LEU SEQRES 17 B 218 ARG SER LEU CYS SER GLN HIS VAL GLU ARG HET CF7 A1000 40 HET CF7 B1000 40 HETNAM CF7 (2R)-N~2~-(3-CHLORO-4-CYANOPHENYL)-N~4~-[3- HETNAM 2 CF7 (CYCLOPROPYLMETHYL)-2,4-DIOXO-1-(PROPAN-2-YL)-1,2,3,4- HETNAM 3 CF7 TETRAHYDROQUINAZOLIN-6-YL]MORPHOLINE-2,4-DICARBOXAMIDE FORMUL 3 CF7 2(C28 H29 CL N6 O5) FORMUL 5 HOH *125(H2 O) HELIX 1 AA1 SER A 266 THR A 284 1 19 HELIX 2 AA2 ARG A 288 GLN A 295 1 8 HELIX 3 AA3 SER A 301 LYS A 311 1 11 HELIX 4 AA4 SER A 312 LEU A 338 1 27 HELIX 5 AA5 CYS A 345 MET A 365 1 21 HELIX 6 AA6 GLY A 384 GLY A 392 5 9 HELIX 7 AA7 CYS A 393 LEU A 410 1 18 HELIX 8 AA8 SER A 413 ILE A 426 1 14 HELIX 9 AA9 GLU A 435 THR A 457 1 23 HELIX 10 AB1 ARG A 459 LEU A 466 5 8 HELIX 11 AB2 PRO A 468 GLU A 481 1 14 HELIX 12 AB3 SER B 266 THR B 284 1 19 HELIX 13 AB4 ARG B 288 GLN B 295 1 8 HELIX 14 AB5 ARG B 296 ASN B 298 5 3 HELIX 15 AB6 SER B 301 LYS B 311 1 11 HELIX 16 AB7 SER B 312 ARG B 337 1 26 HELIX 17 AB8 CYS B 345 MET B 365 1 21 HELIX 18 AB9 GLU B 386 GLY B 392 5 7 HELIX 19 AC1 CYS B 393 ALA B 409 1 17 HELIX 20 AC2 SER B 413 ILE B 426 1 14 HELIX 21 AC3 GLU B 435 THR B 457 1 23 HELIX 22 AC4 ARG B 459 LEU B 466 5 8 HELIX 23 AC5 PRO B 468 ARG B 482 1 15 SHEET 1 AA1 3 TYR A 369 ASN A 370 0 SHEET 2 AA1 3 THR A 375 PHE A 378 -1 O THR A 375 N ASN A 370 SHEET 3 AA1 3 LYS A 381 GLY A 383 -1 O GLY A 383 N VAL A 376 SHEET 1 AA2 3 TYR B 369 ASN B 370 0 SHEET 2 AA2 3 THR B 375 PHE B 378 -1 O THR B 375 N ASN B 370 SHEET 3 AA2 3 LYS B 381 GLY B 384 -1 O LYS B 381 N PHE B 378 SITE 1 AC1 13 GLN A 286 LEU A 287 CYS A 320 HIS A 323 SITE 2 AC1 13 LEU A 324 MET A 365 ALA A 368 PHE A 377 SITE 3 AC1 13 PHE A 378 PHE A 388 ILE A 400 HIS A 479 SITE 4 AC1 13 HOH A1106 SITE 1 AC2 11 GLN B 286 CYS B 320 HIS B 323 LEU B 324 SITE 2 AC2 11 VAL B 361 MET B 365 ALA B 368 PHE B 377 SITE 3 AC2 11 ILE B 400 HIS B 479 HOH B1109 CRYST1 99.211 99.211 126.332 90.00 90.00 120.00 P 61 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010080 0.005819 0.000000 0.00000 SCALE2 0.000000 0.011639 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007916 0.00000